What is it about?
An observational study comparing pts at ICU receiving polyB in combination with another antibiotic (resistant in vitro) and polyB as the single agent.
Featured Image
Why is it important?
We showed that there was a significant improvemnt in 30-d mortality in patients who received polyB in combination.
Perspectives
Evidence for combination therapy for MDR GNB is still scarce. Our study suggests that against A. baumannii and P. aeruginosa in patients at ICU, the use of polyB plus a second antibiotic , even without in vitro susceptibility, may improve patients outcomes in comparison with those who received polyB alone.
Professor Alexandre P Zavascki
Universidade Federal do Rio Grande do Sul
Read the Original
This page is a summary of: Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections, Antimicrobial Agents and Chemotherapy, August 2015, ASM Journals,
DOI: 10.1128/aac.00494-15.
You can read the full text:
Contributors
The following have contributed to this page
